Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
Trial details
- Registry ID
- NCT03755791
- Phase
- Phase 3
The FDA approved Atezolizumab (Tecentriq) on 18 May 2016.
Drug identity checked against registry records
Also recorded as Tecentriq; Tecentriq (Brand name); Tecentriq®
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2016-05-18Day | Atezolizumab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761034", "applicant_as_listed_by_fda": "GENENTECH INC", "brand_names": ["TECENTRIQ"], "active_ingredients": ["ATEZOLIZUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20160518", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |